CLDN15 and breast cancer: Gene expression-based signatures to predict physiological process or prognosis such as the E/S.score or the CV score (CLDN15/VIM) in MPM [10, 11, 62], as well as response to treatment is becoming popular, and some of them have been evaluated in phase 3 clinical trials for breast cancer [63].